PSMA PET/CT时代原发性转移性前列腺癌发病率增加:一项基于人群的分析
该基于人群的队列研究纳入2010至2023年荷兰癌症登记处所有新诊断前列腺癌男性,以诊断年份作为PSMA PET/CT用于初始分期的可及性替代指标。结果显示总体年龄标化发病率略降(EAPC=-0.2%,p=0.64),但盆腔淋巴结阳性仅存和远处转移前列腺癌的发病率上升(EAPC分别为4.6%和4.1%,均p<0.001)。在≥1个高危特征患者中,PSMA PET/CT可及性增加与盆腔淋巴结和/或远处转移检出 odds 升高相关。
要点
- 2010至2023年荷兰前列腺癌总体年龄标化发病率略降(EAPC=-0.2%,p=0.64)。
- 盆腔淋巴结阳性仅存和远处转移前列腺癌的年龄标化发病率上升(EAPC分别为4.6%和4.1%,均p<0.001)。
- ≥1个高危特征患者中,PSMA PET/CT广泛可及期较有限可及期检出盆腔淋巴结和/或远处转移的OR为1.65。
核心结论
- PSMA PET/CT在临床实践中的实施似乎与前列腺癌向盆腔淋巴结阳性和远处转移的显著分期迁移相关。
- 探索性分析还提示更多采用姑息而非治愈性治疗。
- 需要进一步研究评估对临床结局的影响。
研究设计与样本
- 基于人群的队列研究,纳入2010至2023年荷兰癌症登记处所有诊断前列腺癌的男性。
- 以诊断年份作为PSMA PET/CT用于初始分期的可及性和使用情况的替代指标。
- 计算总体和分期特异性欧洲年龄标化发病率(ESR)及估计年度百分比变化(EAPC)。
- 在≥1个高危特征患者中,采用逻辑回归评估诊断年份与盆腔淋巴结和/或远处转移检出之间的关联。
- 进行探索性分析评估治疗变化。
主要发现
- 2010至2023年,前列腺癌总体ESR略降(EAPC=-0.2%,p=0.64)。
- 盆腔淋巴结阳性仅存前列腺癌ESR上升(EAPC=4.6%,p<0.001),远处转移前列腺癌ESR上升(EAPC=4.1%,p<0.001)。
- ≥1个高危特征患者中,PSMA PET/CT可及性增加期(OR=1.33)和广泛可及期(OR=1.65)较有限可及期更常检出盆腔淋巴结和/或远处转移。
- 接受全身治疗的患者比例从38.7%升至42.0%(OR=1.15)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究评估对临床结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the effects of prostate-specific membrane antigen (PSMA) PET/CT use for primary staging on nationwide stage-specific prostate cancer (PCa) incidence rates and treatment patterns. METHODS: For this population-based cohort study, all men diagnosed with PCa in the Netherlands from 2010 to 2023 were identified in the Netherlands Cancer Registry. Year of diagnosis was used as proxy measure for PSMA PET/CT availability and use for primary staging. Overall and stage-specific European age-standardized incidence rates (ESR) and estimated annual percentages change (EAPC) were calculated. Among patients with ≥ 1 high-risk feature, logistic regression was performed to assess the association between year of diagnosis and detection of pelvic lymph node and/or distant metastases. Exploratory analyses were conducted to assess changes in treatment. RESULTS: From 2010 to 2023, the ESR of PCa declined slightly (EAPC=-0.2%, p = 0.64). Meanwhile, the ESR of pelvic node-positive only and distant metastatic PCa increased (EAPC = 4.6% [p < 0.001] and 4.1% [p < 0.001]). Patients with ≥ 1 high-risk feature were more often diagnosed with pelvic lymph node and/or distant metastases in the years with increasing (OR = 1.33) and widespread (OR = 1.65) access compared to the period with limited access to PSMA PET/CT for primary staging. Meanwhile, the proportion of patients that received systemic therapy increased from 38.7 to 42.0% (OR = 1.15). CONCLUSION: The implementation of PSMA PET/CT in clinical practice, appears to be associated with a substantial stage shift towards pelvic node-positive and distant metastatic PCa. Exploratory analyses also suggest more frequent treatment with palliative, rather than curative intent. Further research is needed to evaluate effects on clinical outcomes.
引用
- Heesterman BL, Peters M, Oprea-Lager DE, et al. Increased incidence of primary metastatic prostate cancer in the era of PSMA PET/CT: a population-based analysis. Eur J Nucl Med Mol Imaging. 2025. PMID: 40627159. doi:10.1007/s00259-025-07431-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。